Benitec's (BNTC) Capital Raise Provides Support For Regulatory Filing - Citizens
Tweet Send to a Friend
Citizens analyst Silvan Tuerkcan reiterated a Market Outperform rating and $22.00 price target on Benitec BioPharma (NASDAQ: BNTC).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
